EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

Magdalena Benda, Patrick Reimann, Wolfgang Willenbacher, Eberhard Gunsilius, Katja Weisel, Irene Strassl, Maria Theresa Krauth, Stefan Knop, Thomas Winder, Normann Steiner

Annals of Hematology · 18.06.2026 · 105 (9)

DOI: 10.1007/s00277-026-07140-8 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of Hematology, online erschienen am 18.06.2026. Verfasst von Magdalena Benda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, Feldkirch Academic Teaching Hospital, Feldkirch, Austria. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Immunotherapy, Adoptive, Infections, Multiple Myeloma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Innsbruck and Medical University of Innsbruck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T-cell–redirecting therapies have transformed the treatment of relapsed/refractory multiple myeloma (RRMM) but are associated with substantial infection risk. We systematically reviewed infections after CAR T-cell therapy and bispecific antibodies (BsAbs), focusing on incidence, timing, pathogens, risk factors, and prevention. Following PRISMA guidelines, we searched PubMed through May 22, 2026, and included studies reporting infectious outcomes in RRMM patients treated with CAR-T cells or BsAbs. A total of 123 predominantly early-phase, non-comparative studies were analyzed. Across BCMA-directed CAR-T products and BsAbs, infections were frequent (any-grade incidence ~ 40–80%), with highest risk early after CAR-T infusion and during the first months of BsAb therapy. Grade ≥ 3 infections were common and exceeded 50% in several BsAb cohorts. Fatal infections were less frequent but occurred across both CAR-T and BsAb studies. In randomized CAR-T trials, grade 5 infections represented a substantial proportion of treatment-related deaths. Talquetamab showed lower infection rates (47–55%) but relevant mucocutaneous toxicity. Viral and bacterial pathogens predominated; CMV reactivation, invasive fungal infections, and Pneumocystis jirovecii pneumonia, particularly without prophylaxis, were also reported. Risk factors included neutropenia, corticosteroid/tocilizumab exposure, and hypogammaglobulinemia. Antiviral and Pneumocystis jirovecii pneumonia (PJP) prophylaxis and, most notably, immunoglobulin replacement reduced infections, though residual risk persisted. Real-world data suggest higher infection-related healthcare use and mortality with BsAbs versus CAR-T therapy. Extended dosing intervals may reduce infections, particularly severe infections, while preserving efficacy. Infectious toxicity remains a key limitation. Risk is particularly high with BCMA-targeted therapies and continuous BsAb administration. Tailored prophylaxis, early immunoglobulin replacement, and response-adapted treatment strategies, including extended dosing intervals, may improve safety and outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificImmunotherapy, AdoptiveInfectionsMultiple MyelomaHumans

Stichwörter der Autor:innen

Bispecific antibodiesCAR-T cellsImmunosuppressionInfectious complicationsMultiple myeloma

Substanzen

Antibodies, Bispecific

Autor:innen und Institutionen

  • Department of Internal Medicine II, Feldkirch Academic Teaching Hospital, Feldkirch, Austria.
  • Faculty of Medical Sciences, Private University of the Principality of Liechtenstein, Triesen, Principality of Liechtenstein.
  • Molecular Biology Laboratory, Vorarlberg Institute for Vascular Investigation and Treatment, Dornbirn, Austria.
  • Department of Internal Medicine V, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
  • Connect to Cure, Syndena GmbH, Innsbruck, Austria.
  • Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg-Eppendorf, Hamburg, Germany.

Förderung

  • University of Innsbruck and Medical University of Innsbruck

Zitieren

APA

Benda, M., Reimann, P., Willenbacher, W., Gunsilius, E., Weisel, K., Strassl, I., Krauth, M. T., Knop, S., Winder, T., & Steiner, N. (2026). Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review. Annals of Hematology, 105(9). https://doi.org/10.1007/s00277-026-07140-8

Vancouver

Benda M, Reimann P, Willenbacher W, Gunsilius E, Weisel K, Strassl I, et al. Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review. Annals of Hematology. 2026;105(9). doi:10.1007/s00277-026-07140-8

BibTeX
@article{Benda2026,
  author = {Benda, Magdalena and Reimann, Patrick and Willenbacher, Wolfgang and Gunsilius, Eberhard and Weisel, Katja and Strassl, Irene and Krauth, Maria Theresa and Knop, Stefan and Winder, Thomas and Steiner, Normann},
  title = {Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {9},
  doi = {10.1007/s00277-026-07140-8}
}
Kostenlos starten →